Back to Search
DANIEL DEANGELO, M.D.,PH.D.
M.D.,PH.D.
Hematology & Oncology Physician
NPI: 1134104920IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
81332(MA)
Education
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
Class of 1993
Research & Publications (20)
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
PMID 17344466·Blood·2007
3-trial
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
PMID 16902153·Blood·2006
3-trial
The treatment of adolescents and young adults with acute lymphoblastic leukemia.
PMID 16304369·Hematology Am Soc Hematol Educ Program·2005
8-other
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
PMID 15297408·Clin Cancer Res·2004
8-other
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
PMID 19663825·Br J Haematol·2009
3-trial
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
PMID 18670778·Cancer Chemother Pharmacol·2009
3-trial
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
PMID 19556425·Blood·2009
3-trial
Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.
PMID 19008459·Blood·2009
3-trial
A forgotten cause of kidney injury in chronic myelomonocytic leukemia.
PMID 19185401·Am J Kidney Dis·2009
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 BINNEY ST, DANA-FARBER CANCER INSTITUTE
BOSTON, MA 02115 - Phone
- (617) 632-2645
Quick Facts
- NPI
- 1134104920
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile